Barclays analyst Gena Wang assigned a Buy rating to Cellectis SA (CLLS – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.95.
Wang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Vir Biotechnology, and PTC Therapeutics. According to TipRanks, Wang has an average return of 11.8% and a 44.99% success rate on recommended stocks.
Currently, the analyst consensus on Cellectis SA is a Strong Buy with an average price target of $7.67.
See Insiders’ Hot Stocks on TipRanks >>
CLLS market cap is currently $109M and has a P/E ratio of -0.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Read More on CLLS:
- Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
- Monthly information on share capital and company voting rights
- Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
- Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
- Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
